Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None PLAccessory Mutations: None

PR Other Mutations: L19I • I62V • L63P • C67Y

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible Susceptible indinavir/r (IDV/r) lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

Mutation scoring: PR

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

M41L • T215Y NRTI Mutations:

NNRTI Mutations:

RT Other Mutations: K20R • S134SR • V245K • K277R • K281R • T286A • I293V • E297K

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC) Low-Level Resistance zidovudine (AZT) High-Level Resistance stavudine (D4T) High-Level Resistance didanosine (DDI) Intermediate Resistance emtricitabine (FTC) Susceptible lamivudine (3TC) Susceptible

tenofovir (TDF) Low-Level Resistance Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR) Susceptible efavirenz (EFV) Susceptible etravirine (ETR) Susceptible nevirapine (NVP) Susceptible rilpivirine (RPV) Susceptible

RT comments

Total

M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced dd1, ABC and TDF susceptibility.

T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.

10

10

Drug resistance mutation scores of NRTI:

15

10

10

25 85 65 35 5 5 25

Download CSV DDI 0 FTC 0 3TC 0 TDF 0 0 0 10 5 5 10 40 15 0 0 10

HIVDB 9.5.1 (2023-11-05) Mutation scoring: RT

No drug resistance mutations were found for NNRTI.

ABC

AZT

D4T 15